Cargando…
Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results
This report presents our experience with T therapy in a cohort of T-deficient men on active surveillance (AS) for Gleason 3 + 3 and Gleason 3 + 4 prostate cancer (PCa). A retrospective chart review identified 28 men with T deficiency who underwent T therapy (T group) for at least 6 months while on A...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736350/ https://www.ncbi.nlm.nih.gov/pubmed/26306850 http://dx.doi.org/10.4103/1008-682X.160270 |
_version_ | 1782413264960880640 |
---|---|
author | Kacker, Ravi Hult, Mariam San Francisco, Ignacio F Conners, William P Rojas, Pablo A Dewolf, William C Morgentaler, Abraham |
author_facet | Kacker, Ravi Hult, Mariam San Francisco, Ignacio F Conners, William P Rojas, Pablo A Dewolf, William C Morgentaler, Abraham |
author_sort | Kacker, Ravi |
collection | PubMed |
description | This report presents our experience with T therapy in a cohort of T-deficient men on active surveillance (AS) for Gleason 3 + 3 and Gleason 3 + 4 prostate cancer (PCa). A retrospective chart review identified 28 men with T deficiency who underwent T therapy (T group) for at least 6 months while on AS for PCa. A comparison group of 96 men on AS for PCa with untreated T deficiency (no-T group) was identified at the same institution. The AS protocol followed a modified Epstein criteria and allowed inclusion of men with a single core of low-volume Gleason 3 + 4 PCa. Mean age was 59.5 and 61.3 years, and mean follow-up was 38.9 and 42.4 months for the T and no-T groups, respectively. Of all 28 men in the T group, 3 (10.7%) men developed an increase in Gleason score while on AS. Of 22 men in the T group with Gleason 3 + 3 disease, 7 (31.8%) men developed biopsy progression including 3 men (13.6%) who developed Gleason 3 + 4 PCa. Of 6 men with Gleason 3 + 4 disease at baseline, 2 (33.3%) men developed an increase in tumor volume, and none developed upgrading beyond Gleason 3 + 4. All 96 men in the no-T group had Gleason 3 + 3 disease at baseline and, 43 (44.7%) developed biopsy progression, including 9 men (9.38%) with upgrading to Gleason 7 (3 + 4). Biopsy progression rates were similar for both groups and historical controls. Biopsy progression in men on AS appears unaffected by T therapy over 3 years. Prospective placebo-controlled trials of T therapy in T-deficient men on AS should be considered given the symptomatic benefits experienced by treated men. |
format | Online Article Text |
id | pubmed-4736350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47363502016-02-04 Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results Kacker, Ravi Hult, Mariam San Francisco, Ignacio F Conners, William P Rojas, Pablo A Dewolf, William C Morgentaler, Abraham Asian J Androl Invited Original Article This report presents our experience with T therapy in a cohort of T-deficient men on active surveillance (AS) for Gleason 3 + 3 and Gleason 3 + 4 prostate cancer (PCa). A retrospective chart review identified 28 men with T deficiency who underwent T therapy (T group) for at least 6 months while on AS for PCa. A comparison group of 96 men on AS for PCa with untreated T deficiency (no-T group) was identified at the same institution. The AS protocol followed a modified Epstein criteria and allowed inclusion of men with a single core of low-volume Gleason 3 + 4 PCa. Mean age was 59.5 and 61.3 years, and mean follow-up was 38.9 and 42.4 months for the T and no-T groups, respectively. Of all 28 men in the T group, 3 (10.7%) men developed an increase in Gleason score while on AS. Of 22 men in the T group with Gleason 3 + 3 disease, 7 (31.8%) men developed biopsy progression including 3 men (13.6%) who developed Gleason 3 + 4 PCa. Of 6 men with Gleason 3 + 4 disease at baseline, 2 (33.3%) men developed an increase in tumor volume, and none developed upgrading beyond Gleason 3 + 4. All 96 men in the no-T group had Gleason 3 + 3 disease at baseline and, 43 (44.7%) developed biopsy progression, including 9 men (9.38%) with upgrading to Gleason 7 (3 + 4). Biopsy progression rates were similar for both groups and historical controls. Biopsy progression in men on AS appears unaffected by T therapy over 3 years. Prospective placebo-controlled trials of T therapy in T-deficient men on AS should be considered given the symptomatic benefits experienced by treated men. Medknow Publications & Media Pvt Ltd 2016 2015-08-21 /pmc/articles/PMC4736350/ /pubmed/26306850 http://dx.doi.org/10.4103/1008-682X.160270 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Invited Original Article Kacker, Ravi Hult, Mariam San Francisco, Ignacio F Conners, William P Rojas, Pablo A Dewolf, William C Morgentaler, Abraham Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title_full | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title_fullStr | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title_full_unstemmed | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title_short | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results |
title_sort | can testosterone therapy be offered to men on active surveillance for prostate cancer? preliminary results |
topic | Invited Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736350/ https://www.ncbi.nlm.nih.gov/pubmed/26306850 http://dx.doi.org/10.4103/1008-682X.160270 |
work_keys_str_mv | AT kackerravi cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT hultmariam cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT sanfranciscoignaciof cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT connerswilliamp cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT rojaspabloa cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT dewolfwilliamc cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults AT morgentalerabraham cantestosteronetherapybeofferedtomenonactivesurveillanceforprostatecancerpreliminaryresults |